Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Molecular Therapy. Methods & Clinical Development|January 11, 2024
Intrathecal delivery of a bicistronic AAV9 vector expressing β-hexosaminidase A corrects Sandhoff disease in a murine model: A dosage studyAlex E Ryckman, Natalie M Deschenes, Brianna M Quinville, et al.
Journal of Viral Hepatitis|July 3, 2004
A multicentre study of the usefulness of liver biopsy in hepatitis CV G Bain, M Bonacini, S Govindarajan, et al.
Alimentary Pharmacology & Therapeutics|January 21, 2006
Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practiceS S Lee, V G Bain, K Peltekian, et al.
International Journal of Molecular Sciences|June 10, 2023
Biochemical Correction of GM2 Ganglioside Accumulation in AB-Variant GM2 GangliosidosisNatalie M Deschenes, Camilyn Cheng, Alex E Ryckman, et al.
International Journal of Molecular Sciences|April 14, 2026
Correction: Vyas et al. Efficacy of Adeno-Associated Virus Serotype 9-Mediated Gene Therapy for AB-Variant GM2 Gangliosidosis. Int. J. Mol. Sci. 2023, 24, 14611Meera Vyas, Natalie M Deschenes, Karlaina J L Osmon, et al.
Gut|May 20, 2006
Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapyM Sherman, E M Yoshida, M Deschenes, et al.
Neurophotonics|March 25, 2020
Anisotropic light scattering from myelinated axons in the spinal cordDamon DePaoli, Alicja Gasecka, Mohamed Bahdine, et al.
International Journal of Molecular Sciences|October 14, 2023
Efficacy of Adeno-Associated Virus Serotype 9-Mediated Gene Therapy for AB-Variant GM2 GangliosidosisMeera Vyas, Natalie M Deschenes, Karlaina J L Osmon, et al.
Current Oncology (Toronto, Ont.)|October 25, 2013
Magnitude of change in alpha-fetoprotein in response to transarterial chemoembolization predicts survival in patients undergoing liver transplantation for hepatocellular carcinomaM Bhat, M Hassanain, E Simoneau, et al.
Journal of Viral Hepatitis|December 20, 2007
Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3J Powis, K M Peltekian, S S Lee, et al.
Pageof 3